// App-Quantinova.ai

TCT-411 : Risk and timing of clinical events according to diabetic status of patients treated with Everolimus-Eluting Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting stent: 2-Year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials

Researchers

Presenter

  • Carlos Campos

Principal Investigators

  • Alexandre Abizaid

  • Adriano Caixeta

  • Antonio Bartorelli

  • Robert Whitbourn

  • Marco Perin

Medical Centers

  • University of Milan, Milan, Italy

  • de Sao Paulo, Sao Paulo, Brazil

  • Hospital Israelita Albert Einstein, Sao Paulo, Brazil

  • St Vincents Hospital, University of Melbourne, Melbourne, Victoria, Australia

  • Hospital Albert Einstein, Sao Paulo, Sao Paulo, Brazil

  • ICU, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

Locations

  • Brazil

  • Italy

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Myocardial infarction

  • Venous thrombosis

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved